PROCESS FOR THE MANUFACTURE OF GLUCAGON

FGF21 VARIANT POLYPEPTIDE MOLECULES AND APPLICATION THEREOF

METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF

CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS

GLP-1 DERIVATIVES AND USES THEREOF

FUSION PROTEIN HAVING TRIPLE ACTIVITY AND USE THEREOF

NOVEL TRIPLE GLP-1/GIP/GLUCAGON RECEPTOR AGONIST AND A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY COMPRISING THE SAME

PROCESSES FOR SYNTHESIZING GLUCAGON-LIKE-PEPTIDE 2 (GLP-2) ANALOGUES

METHODS OF DULAGLUTIDE PURIFICATION USING HYDROPHOBIC INTERACTION CHROMATOGRAPHY

FGF21 AND GLP1 DOUBLE GENE-MODIFIED MESENCHYMAL STEM CELL AND USE IN TREATING A METABOLIC DISEASE

METHOD FOR PREPARING LIRAGLUTIDE

DUAL GLP-1 AND GIP RECEPTOR AGONIST PHARMACEUTICAL COMPOSITION AND USE THEREOF

CRYSTALLISATION OF A PROTEIN CAPABLE OF CRYSTALLIZING UNDER SALTING-IN CONDITIONS USING MULTIPLE PROTEIN FEEDS

ULTRA-LONG-ACTING PLATFORM COMPRISING FC-ADVANCED FATTY ACID CHAIN

POLYPEPTIDE COMBINATIONS AND USES THEREOF

INCRETIN ANALOG AND USE THEREOF

LONG-ACTING DUAL-AGONIST COMPOUND

A REPLICATIVE ONCOLYTIC ADENOVIROUS CAPABLE OF INHIBITING TUMOR PROGRESSION AND PROLONGING SURVIVAL TIME IN TUMOR-BEARING INDIVIDUALS AND USE THEREOF

PHYSIOLOGICALLY-ACTIVE PEPTIDE DERIVATIVE FOR TREATMENT OF EYE DISEASES, PHARMACEUTICAL COMPOSITION, NASAL/NASAL DROP PREPARATION, AND USE OF PHYSIOLOGICALLY-ACTIVE PEPTIDE DERIVATIVE

NOVEL PEPTIDE HORMONE ANALOGUES

A PROCESS FOR THE PREPARATION OF GLUCAGON

PROCESS FOR THE PREPARATION OF SEMAGLUTIDE

ACYLATED GLUCAGON ANALOGUES

METHOD FOR PRODUCING DUAL FUNCTION PROTEINS AND ITS DERIVATIVES

METHOD OF CONJUGATION OF CYS-MABS

COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS

GLUCAGON-LIKE PEPTIDE-2 COMPOSITIONS AND METHODS OF MAKING AND USING SAME

COMPOSITIONS AND METHODS FOR ORAL DELIVERY

SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID

PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST

Soluble GLP1/GIP/NPY2 Receptor Triple Agonists

MODIFIED GIP PEPTIDE ANALOGUES

FUSION PROTEINS COMPRISING AN IMPROVED GLP-1 RECEPTOR AGONIST AND USES THEREOF

NOVEL COMPOUNDS

GLP-1 RECEPTOR ANTAGONISTS

GLP-1 ANALOGUE COMPOSITIONS AND PREPARATION METHOD

GLP-1 AND GLUCAGON DUAL AGONIST PEPTIDES WITH IMPROVED BIOLOGICAL STABILITY

COMPOUNDS USEFUL TO TREAT METABOLIC DISORDERS

FUSION PROTEIN AND APPLICATION THEREOF

AGENTS AND METHODS FOR TREATING DISEASE

STAPLE-CONTAINING POLYPEPTIDES AND APPLICATION THEREOF

INCRETIN ANALOGS AND USES THEREOF

PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE

GLUCAGON ANALOGUES AS LONG-ACTING GLP-1/GLUCAGON RECEPTOR AGONISTS IN THE TREATMENT OF FATTY LIVER DISEASE AND STEATOHEPATITIS

Prodrugs of GLP-1 Polypeptide and Uses Thereof

PEPTIDES TRIPLE AGONISTS OF GIP, GLP-1 AND GLP-2

PEPTIDE DUAL AGONISTS OF GIPR AND GLP2R

Polycistronic Expression of Gut Peptides

PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST

FUSION PROTEIN COMPRISING GLP-1, IMMUNOGLOBULIN FC, AND IGF-1 AND USE THEREOF

GLUCAGON RECEPTOR AGONISTS AND CONJUGATES TO GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE ANTAGONISTS

PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST

PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST

PHARMACEUTICAL COMPOSITION COMPRISING POLYPEPTIDE

SUPER LONG-LASTING GLP1 OR GLP1/GIP ANALOGUE DRUG FOR TYPE-2 DIABETES AND OBESITY

DUAL FUNCTION PROTEINS COMPRISING FGF21 MUTANT PROTEIN AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

GLP-1 PRODRUGS AND USES THEREOF

PROCESSES AND INTERMEDIATES FOR PREPARING TIRZEPATIDE

MULTIMERIC POLYPEPTIDES AND USES THEREOF

PROCESS FOR THE PREPARATION OF LIRAGLUTIDE

MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF

GLP-1/GIP DUAL-TARGETED POLYPEPTIDE AND FUSION PROTEIN AND APPLICATIONS THEREOF

GLUCAGON LIKE PEPTIDE 1 (GLP1)-GROWTH DIFFERENTIATION FACTOR 15 (GDF15) FUSION PROTEINS AND USES THEREOF

LIQUID FORMULATIONS OF GLUCAGON ANALOGUES

PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE

FUSION PROTEIN OF GLP-1 AND GDF15 AND USE THEREOF

PEPTIDE ACIDS AS A GLP1R AGONIST AND ANTIBODY-DRUG CONJUGATES THEREOF

AAV VECTORS FOR DELIVERY OF GLP-1 RECEPTOR AGONIST FUSIONS

METHOD OF TREATING DISEASE OR DISORDER USING COMPOSITIONS COMPRISING PHARMACEUTICALLY ACCEPTABLE SALTS OF AMYLIN ANALOGS

FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES

COMPOSITIONS COMPRISING THERAPEUTIC PROTEINS OR PEPTIDES, AND USES THEREOF

METHOD FOR ADJUSTING A PARENTERAL SUPPORT (PS) VOLUME IN A HUMAN SUBJECT

PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE

Injection pen for subcutaneous administration of a peptide

Multi-Agonist and Use Thereof

GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES

GIP/GLP1 CO-AGONIST COMPOUNDS

DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDE

PHARMACEUTICAL COMPOSITION OF GLP-1 RECEPTOR AND GIP RECEPTOR DUAL AGONIST, AND USE THEREOF

METHOD FOR PRODUCING AN ANTIBODY PEPTIDE CONJUGATE

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASES, CONTAINING GLUCAGON-LIKE PEPTIDE-1 AND INTERLEUKIN-1 RECEPTOR ANTAGONIST

IGG FC VARIANTS FOR VETERINARY USE

POTENT AND STABLE POLYPEPTIDE ANALOGUES VIA SERINE/THREONINE LIGATION

DUAL-TARGET FUSION PROTEINS COMPRISING FGF21 AND GLP-1, CONNECTED THROUGH A FC PORTION OF AN IMMUNOGLOBULIN

STABLE GLP-1 ANALOGS FOR THE TREATMENT OF HUMAN DISEASE AND DISORDERS

DOSAGE REGIME

FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES

OBESITY TREATMENT AND PREVENTION METHODS

GLUCAGON PROMOTER FOR DIABETES GENE THERAPY

CONSTRUCTS AND METHODS FOR INCREASED EXPRESSION OF POLYPEPTIDES

INCRETIN ANALOGS AND USES THEREOF

GIP/GLP1 CO-AGONIST COMPOUNDS

EXTENDED RECOMBINANT POLYPEPTIDES AND COMPOSITIONS COMPRISING SAME

LONG ACTING GLUCAGON LIKE POLYPEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND METHODS OF USE

ACTIVATING APPENDAGES TO INDUCE POLYPHARMACOLOGY IN PEPTIDE HORMONE ANALOGUES, INCLUDING DUAL GLP-1R / GIP AGONISM

PEPTIDE-DRUG CONJUGATES FOR TREATMENT OF NEURODEGENERATIVE DISEASES

PROCESS FOR THE PREPARATION OF TIRZEPATIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Long-Acting GLP-1 Compound

GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS AND USES THEREOF

PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE

DPP-4 INHIBITOR AND PRODUCTION METHOD THEREFOR

Processes and intermediates for preparing tirzepatide

FUSION COMPOUNDS AND USES THEREOF

GLP-1/GIP DUAL AGONISTS

PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST

PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1 AGONIST, AN INSULIN AND METHIONINE

Modulators of G-Protein Coupled Receptors

CELL-FREE METHODS AND COMPOSITIONS COMPRISING TAGLESS THERAPEUTIC HORMONES

Novel GLP-1 Analogues

PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST

Novel bispecific protein and use thereof

FGF21 COMPOUND / GLP-1R AGONIST COMBINATIONS WITH OPTIMIZED ACTIVITY RATIO

New Peptides as Potent and Selective GIP Receptor Agonists

POLYPEPTIDE DERIVATIVE WITH DUAL GLP-1R AND GIPR TARGETING AGONISTIC EFFECT, AND PREPARATION METHOD AND USE THEREOF

Fusion protein and its preparation method for intermediate polypeptide of Semaglutide

PURIFICATION OF LIRAGLUTIDE

NOVEL COMPOUNDS

IONIC LIQUID COMPOSITIONS

GLP-1/GIP DUAL AGONIST, PREPARATION METHOD AND USE THEREOF

FGF21 COMPOUND / GLP-1R AGONIST COMBINATIONS WITH OPTIMIZED ACTIVITY RATIO

IONIC LIQUID COMPOSITIONS

METHODS OF PRODUCING FC-CONTAINING PROTEINS

NOVEL STATIONARY PHASE FOR LARGE SCALE REVERSE-PHASE HPLC PURIFICATION

Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and uses thereof

ELP FUSION PROTEINS FOR CONTROLLED AND SUSTAINED RELEASE

Compositions comprising pharmaceutically acceptable salts of amylin analogs and uses thereof

COMPOSITIONS AND METHODS FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASE

CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS

GLUCAGON ANALOG AND MEDICAL USE THEREOF

Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and uses thereof

THERAPEUTICS AND METHODS FOR TREATING OR AMELIORATING METABOLIC DISORDERS

Glycosylated Neuropeptide Derivative, Pharmaceutical Composition, Intranasal/Nasal Drop Formulation, and Use of Pharmaceutical Composition

PREPARATION AND APPLICATION OF POLYPEPTIDE

ORAL GLP RECEPTOR AGONISTS

FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES

DUAL-FUNCTION PROTEIN FOR LIPID AND BLOOD GLUCOSE REGULATION

GLP-1 Receptor Agonists Having Improved Pharmacological and Drug Delivery Properties

GLP1/GIP/NPY2 RECEPTOR TRIPLE AGONISTS

GLUCAGON LIKE PEPTIDE COMPOUNDS

GLUCAGON-RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS OF USE THEREOF

THIOAMIDE-MODIFIED PEPTIDES AND USES THEREOF

Long-Acting GLP-1 Compound

LONG ACTING GLUCAGON RECEPTOR SELECTIVE PEPTIDES AND METHODS OF USE

Fusion proteins for the treatment of cardiometabolic diseases

GIP AND GLP-1 DUAL RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION, AND USE

METHOD FOR EXPRESSING AND PURIFYING PROTEIN BY USING CSQ-TAG

Pancreatic Islets as Protein Factories

GLP-1 Analogues

SEMAGLUTIDE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Incretin Analogs and Uses Thereof

A USE OF A POLYPEPTIDE COMPOUND IN THE PREPARATION OF DRUGS FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASES AND RELATED INTESTINAL FIBROSIS

AQUEOUS COMPOSITION OF AN ENGINEERED PROTEIN CONSTRUCT COMPRISING AN FC DOMAIN

GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use

DIRECTED CHEMICAL CONJUGATE OF GLUCAGON-LIKE PEPTIDE-2 MUTANT, AND USE THEREOF

GLP-1 ANALOGUE-MODIFIED DIMERS WITH DIFFERENT CONFIGURATIONS, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN TREATMENT OF TYPE II DIABETES

GLP-1R, GIP-R AND/OR GCGR AGONISTS, FORMULATIONS, AND METHODS OF USE

ACYLATED GLUCAGON ANALOGUES

COMPOUNDS AND METHODS FOR EXTENDING HALF LIFE OF BIOMOLECULES

GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF

CONFORMATIONALLY CONSTRAINED GLUCAGON ANALOGUES AND THEIR USE IN GLUCAGON-SINGLE CHAIN INSULIN FUSION PROTEINS

GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ANTAGONISTS

FGF21 and GLP1 DOUBLE GENE-MODIFIED MESENCHYMAL STEM CELL AND USE IN TREATING A METABOLIC DISEASE

SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID

PRODRUGS AND USES THEREOF

HUMAN GLP-1 POLYPEPTIDE VARIANT AND USE THEREOF

GLUCAGON ANALOGUES

GLUCAGON-LIKE PEPTIDE-2 COMPOSITIONS AND METHODS OF MAKING AND USING SAME

SYNTHESIS OF TEDUGLUTIDE

FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES

COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE

LONG-ACTING GLUCAGON DERIVATIVE

Compositions and Methods for Peptide Production

Glucagon-like peptide 1 receptor agonists and uses thereof

FUSION PROTEIN INCLUDING GLP-1 RECEPTOR AGONIST, AND ANTI-OSCAR ANTIBODY AND USE THEREOF

AMINO DIACIDS CONTAINING PEPTIDE MODIFIERS

ELEVATED INTRACRANIAL PRESSURE TREATMENT

A PEPTIDE WITH DISULFIDE BONDS AND INHIBITORY ACTIVITY AGAINST SERINE PROTEASES, DERIVED HYBRID PEPTIDES THEREOF, AND USES THEREOF

PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1

VIRAL VECTOR ENCODING GLP-1 RECEPTOR AGONIST FUSIONS AND USES THEREOF IN TREATING METABOLIC DISEASES IN FELINES

ACYLATED GLP-1/GLP-2 DUAL AGONISTS

GLP-1, GIP AND GLUCAGON RECEPTOR TRIPLE AGONISTS

GLP-1/GIP DUAL AGONIST, LONG-ACTING CONJUGATE THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

OBESITY TREATMENT AND PREVENTION METHODS

VIRAL VECTORS ENCODING GLP-1 RECEPTOR AGONIST FUSIONS AND USES THEREOF IN TREATING METABOLIC DISEASES

COILED COIL IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF

GLP-1R/GCGR Dual Target Agonist Polypeptide Derivative for Treatment of Hepatic Fibrosis Associated with Viral Hepatitis

GLUCAGON DELIVERY VIA ENZYMATIC ACTUATION

GLP-1 AND GLUCAGON DUAL AGONIST PEPTIDES WITH IMPROVED BIOLOGICAL STABILITY

MODULATORS OF G-PROTEIN COUPLED RECEPTORS

FUSION PROTEIN INCLUDING GLUCAGON-LIKE PEPTIDE-1 AND INTERLEUKIN-1 RECEPTOR ANTAGONIST AND USE THEREOF

GLP-1 AND GIP RECEPTOR CO-AGONISTS

A PROCESS FOR THE PREPARATION OF SEMAGLUTIDE AND SEMAPEPTIDE

Co-agonists of the GLP-1 and amylin receptors

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof

GLP-1/GLUCAGON DUAL AGONIST FUSION PROTEIN

COMPOSITIONS AND METHODS FOR CONTROLLING BLOOD SUGAR LEVELS USING NANOCAPSULE-BASED DRUG DELIVERY SYSTEM

METHOD FOR THE EFFICIENT EXPRESSION AND PURIFICATION AND APPLICATION OF A RECOMBINANT FUSION PROTEIN OF MANNASE AND HOMOLOGUES THEREOF AND GLP-1

GLP RECEPTOR AGONISTS

STAPLED LACTAM CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS

GLP-1 RECEPTOR ANTAGONISTS

CO-AGONISTS AT GLP-1 AND GIP RECEPTORS SUITABLE FOR ORAL DELIVERY

SERUM ALBUMIN-BINDING POLYPEPTIDES

STAPLED OLEFIN CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS

GLP-1R AGONIST / FGF21 FUSION PROTEINS

GIP/GLP1 CO-AGONIST COMPOUNDS

Fusion protein comprising fibroblast growth factor 19 (FGF 19) and glucagon-like peptide-1

ARTIFICIAL SECRETION PEPTIDES FOR HETEROLOGOUS PROTEIN PRODUCTION

GLP-1R AGONISTIC PEPTIDES WITH REDUCED ACTIVITY

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

NOVEL METHOD FOR PREPARING LONG-ACTING DRUG CONJUGATE THROUGH PREPARATION OF INTERMEDIATE

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

Prodrugs and uses thereof

IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE

LONG-ACTING GLP-1 AND GLUCAGON RECEPTOR DUAL AGONIST

METHOD FOR IMPROVING SOLUBILITY OF PROTEIN AND PEPTIDE BY USING IMMUNOGLOGULIN FC FRAGMENT LINKAGE

GLP-1 AGONIST POLYPEPTIDE COMPOUND AND SALT THEREOF, SYNTHESIS METHOD THEREFOR AND USE THEREOF

PROCESS FOR PREPARING A GLP-1/GLUCAGON DUAL AGONIST

METHOD FOR PRODUCING DUAL FUNCTION PROTEINS AND ITS DERIVATIVES

Incretin Analogs and Uses Thereof

Compositions and methods for peptide production

LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLUCAGON DERIVATIVE

DUAL-AGONIST COMPOUND FOR BOTH GLP-1 AND GIP RECEPTORS AND APPLICATION THEREOF

Polypeptide Compounds and Use Thereof in the Prevention or Treatment of Diabetes or Diabetic Complications

STRUCTURALLY-STABILIZED GLUCAGON-LIKE PEPTIDE 1 PEPTIDES AND USES THEREOF

Polypeptide Derivative Having Dual Receptor Agonistic Action and Use Thereof

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MUCOSITIS INDUCED BY RADIOTHERAPY, CHEMOTHERAPY, OR COMBINATION THEREOF, COMPRISING GLP-2 DERIVATIVES OR LONG-ACTING CONJUGATE OF SAME

PHARMACEUTICAL COMPOSITIONS FOR GLUCAGON AND GLP-1 CO-AGONIST PEPTIDES

COMPOSITION FOR PREVENTION OR TREATMENT OF HYPERLIPIDEMIA COMPRISING TRIGONAL GLUCAGON/GLP-1/GIP RECEPTOR AGONIST OR CONJUGATE THEREOF AND METHOD USING THE SAME

Modulators of G-protein coupled receptors

QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF

PREPARATION METHOD FOR SEMAGLUTIDE

BRANCHED DISCRETE PEG CONSTRUCTS

CO-AGONISTS AT GLP-1 AND GIP RECEPTORS SUITABLE FOR ORAL DELIVERY

Method for preparing long-acting drug conjugate through preparation of intermediate

LONG-ACTING CONJUGATES OF GLP-2 DERIVATIVES

PEPTIDE CONJUGATES AND METHODS OF USE

TRIPLE AGONIST FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR, GLUCAGON RECEPTOR, AND GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR

STAPLED TRIAZOLE CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS

Long acting glucagon like polypeptide-1 (GLP-1) receptor agonists and methods of use

COMPOSITIONS COMPRISING AT LEAST AN AMYLIN RECEPTOR AGONIST AND A GLP-1 RECEPTOR AGONIST

GLP2 RECEPTOR AGONISTS AND METHODS OF USE

AN IMPROVED PROCESS FOR PREPARATION OF LIRAGLUTIDE

GLP-2 FUSION POLYPEPTIDES AND USES FOR TREATING AND PREVENTING GASTROINTESTINAL CONDITIONS

PROTEIN BLOCKING ASSEMBLY AND METHODS OF MAKING AND USING

MONOMERIC FUSION PEPTIDES AND METHOD OF USE THEREOF

GLP-1 RECEPTOR AGONISTS HAVING IMPROVED PHARMACOLOGICAL AND DRUG DELIVERY PROPERTIES

COMBINATION THERAPY USING GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF OBESITY

N-TERMINAL EXTENSION SEQUENCE FOR EXPRESSION OF RECOMBINANT THERAPEUTIC PEPTIDES

THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES

ACYLATED GLP-1/GLP-2 DUAL AGONISTS

Thioredoxin mutant, preparation method thereof, and application thereof in production of recombinant fusion protein

GIPR ANTIBODY AND FUSION PROTEIN BETWEEN SAME AND GLP-1, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF

PURIFICATION OF GLP-1 ANALOGUES

METHODS OF MAKING INCRETIN ANALOGS

GLP-1 analogues

GLP-1 analogues

FGF21 COMPOUND / GLP-1R AGONIST COMBINATIONS WITH OPTIMIZED ACTIVITY RATIO

PROCESS FOR PRODUCTION OF SOLUBLE RECOMBINANT PEPTIDES

Long-lasting GLP1 analogue drug for type-2 diabetes

IMPROVED PURIFICATION PROCESSES FOR LIRAGLUTIDE

Peptide pharmaceuticals for insulin resistance

FUSION PROTEIN FOR TREATMENT OF METABOLIC DISEASE

Glucagon-receptor selective polypeptides and methods of use thereof

PROCESS FOR THE MANUFACTURE OF GLUCAGON

EXENATIDE ANALOG AND USE THEREOF

NOVEL PEPTIDE HORMONE ANALOGUES

Modified GIP peptide analogues

Multi-receptor (GLP-1 receptor, GIP receptor, and Gcg receptor) agonist protein

Highly effective blood-glucose-lowering protein drug

SATIATION PEPTIDES FOR WEIGHT LOSS AND ALTERED TASTE SENSITIVITY

NOVEL METHOD OF PREPARING PROTEIN CONJUGATE

LONG-LASTING GLP1 ANALOGUE DRUG FOR TYPE-2 DIABETES

FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES

NOVEL METHOD FOR PREPARING LONG-ACTING DRUG CONJUGATE THROUGH PREPARATION OF INTERMEDIATE

COMPOSITIONS AND METHODS OF TREATING AND PREVENTING SYSTEMIC COMPLICATIONS OF ACUTE ILLNESS

PROCESS FOR PRODUCTION OF SOLUBLE RECOMBINANT PEPTIDES

LONG-ACTING CONJUGATES OF GLP-2 DERIVATIVES

GIP AND GLP-1 DUAL AGONIST POLYPEPTIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT AND APPLICATION THEREOF

FGF21 FC FUSION PROTEIN, GLP-1 FC FUSION PROTEIN, AND COMBINATION THERAPEUTIC AGENT COMPRISING SAME AND USE THEREOF

METHOD FOR EXPRESSING AND PURIFYING PROTEIN BY USING CSQ-TAG

METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF

COMPOSITIONS AND METHODS FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASE

QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF

TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST

METHOD FOR PREPARING TARGET POLYPEPTIDE BY MEANS OF RECOMBINATION AND SERIES CONNECTION OF FUSED PROTEINS

Mating factor alpha pro-peptide variants

CO-AGONISTS AT GLP-1 AND GIP RECEPTORS SUITABLE FOR ORAL DELIVERY

MULTI-RECEPTOR AGONIST AND MEDICAL USE THEREOF

FUSION PROTEIN CONTAINING FLUORESCENT PROTEIN FRAGMENTS AND USES THEREOF

BISPECIFIC PROTEIN

PROCESS OF PREPARATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR ANALOGS

MODIFIED GLUCAGON MOLECUES AND FORMULATIONS WITH OXIDATION RESISTANCE AND METHODS AND KITS OF EMPLOYING THE SAME

METHODS AND COMPOSITIONS FOR PROTEIN DELIVERY

PERSONALIZED AND TIMED RELEASE OF BIOMOLECULES

PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST